What you wrote mixes a real type of regulatory action (EMA recalls) with a misleading or overgeneralized claim.
What is actually true
The European Medicines Agency (EMA) does sometimes order or recommend withdrawal/recall of medicines when serious risks are discovered.
For example:
- The MS drug Zinbryta (daclizumab) was suspended and recalled after reports of severe brain inflammation (encephalitis), including fatal cases. (European Medicines Agency (EMA))
So yes—EMA can and does recall drugs urgently for brain-related side effects.
What is NOT accurate / needs correction
- “Brain damage is possible even after a single dose” → This is not a universal rule for EMA actions or all drugs.
- It is true for some specific medicines, like levamisole-containing drugs, where rare cases of brain white-matter damage (leukoencephalopathy) can occur even after one dose. (European Medicines Agency (EMA))
- But this does NOT apply to all medications, and definitely not as a general statement.
- “The EMA has ordered the immediate recall of the drugs” → This depends on the exact medicine. EMA does not issue a blanket recall for “drugs” in general.
Bottom line
- ✔ EMA recalls specific medicines when serious risks are proven
- ✔ Some rare drugs can cause severe neurological harm even after one dose
- ❌ But the statement is misleading if presented as a general rule for all medicines
If you want, tell me the name of the drug you’re referring to, and I can explain the exact risk and whether that claim is true for it specifically.
